Intermittent calorie restriction followed for 2 nonconsecutive days per week reduced the liver fat content in patients with ...

Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...

The GLP-1 receptor agonist improved both histology and fibrosis in patients, with additional improvements in their liver ...

Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three ...

Autoimmune hepatitis (AIH) is a chronic, progressive inflammatory liver disease caused by autoimmune reactions, with an unknown etiology. If left untreated, it can progress to cirrhosis, liver failure ...

2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces that it will be ...

which makes its findings extremely "operator-dependent", particularly for initial lesions or small tumors - i.e., in the early stages of the disease, which is a critical time for detection of ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver ... However, their sensitivity for detecting early-stage fibrosis is limited, ...

The ongoing Phase 2b study (CENTRICITY, NCT05623189), fully enrolled in 1Q 2024, evaluates the histological benefit of HTD1801 ... provides greater improvements in markers of liver injury and ...

Liver cancer often goes unnoticed in its early stages, as its symptoms can be subtle or mistaken for other less serious conditions. By the time symptoms, such as unexplained fatigue, loss of ...